This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by García, M. T.
Right arrow Articles by Aguilar, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by García, M. T.
Right arrow Articles by Aguilar, L.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2000, p. 2176-2178, Vol. 44, No. 8
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

In Vitro Activities of Gemifloxacin versus Five Quinolones and Two Macrolides against 271 Spanish Isolates of Legionella pneumophila: Influence of Charcoal on Susceptibility Test Results

M. T. García,1 C. Pelaz,1 M. J. Giménez,2 and L. Aguilar2,*

Spanish National Reference Laboratory, Instituto de Salud Carlos III, Carretera. Majadahonda a Pozuelo, 28220 Majadahonda,1 and Medical Department, SmithKline Beecham Pharmaceuticals, 28034 Madrid,2 Spain

Received 6 March 2000/Returned for modification 11 April 2000/Accepted 3 May 2000

The MICs at which 90% of isolates are inhibited for gemifloxacin, trovafloxacin, and grepafloxacin were low (<= 0.01 µg/ml) for 271 Legionella isolates when they were determined by the broth microdilution method but increased (>= 6 dilutions) when they were determined by the agar dilution method. This was due to the charcoal in the agar dilution medium, as shown by the progressive decrease in the MICs when the charcoal concentrations decreased. As free drug is the active fraction, charcoal binding should be considered.

* Corresponding author. Mailing address: Medical Department, SmithKline Beecham Pharmaceuticals, Valle de la Fuenfría, 3, 28034 Madrid, Spain. Phone: 34-91-334 5275. Fax: 34-91-334 5141. E-mail: lorenzo.aguilar-alfaro{at}sb.com.

Antimicrobial Agents and Chemotherapy, August 2000, p. 2176-2178, Vol. 44, No. 8
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Baltch, A. L., Bopp, L. H., Smith, R. P., Michelsen, P. B., Ritz, W. J. (2005). Antibacterial activities of gemifloxacin, levofloxacin, gatifloxacin, moxifloxacin and erythromycin against intracellular Legionella pneumophila and Legionella micdadei in human monocytes. J Antimicrob Chemother 56: 104-109 [Abstract] [Full Text]  
  • Roch, N., Maurin, M. (2005). Antibiotic susceptibilities of Legionella pneumophila strain Paris in THP-1 cells as determined by real-time PCR assay. J Antimicrob Chemother 55: 866-871 [Abstract] [Full Text]  
  • Yoo, B. K, Triller, D. M, Yong, C.-S., Lodise, T. P (2004). Gemifloxacin: A New Fluoroquinolone Approved for Treatment of Respiratory Infections. The Annals of Pharmacotherapy 38: 1226-1235 [Abstract] [Full Text]  
  • Roig, J., Rello, J. (2003). Legionnaires' disease: a rational approach to therapy. J Antimicrob Chemother 51: 1119-1129 [Abstract] [Full Text]  
  • Edelstein, P. H., Shinzato, T., Doyle, E., Edelstein, M. A. C. (2001). In Vitro Activity of Gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and Its Pharmacokinetics in Guinea Pigs with L. pneumophila Pneumonia. Antimicrob. Agents Chemother. 45: 2204-2209 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»